Autologous Peripheral Blood Progenitor Cell Transplantation for Transformed Diffuse Large-Cell Lymphoma

Bolwell, Brian J.; Kalaycio, Matt; Andrèsen, Steven; Goormastic, Marlene; McBee, M.; Kuczkowski, Elizabeth; Wise, Kimberly; Sobecks, Ronald; Pohlman, Brad

doi:10.3816/clm.2000.n.019

“…Stem cell transplantation has become a treatment option for NHL patients including those with relapsed/ refractory disease, low, intermediate or high grade NHL, and aggressive NHL [1][2][3][4][5][6][9][10]12,[14][15][16][17][18][19]. For relapsed/ refractory NHL, Bu/Cy/VP-16 has been investigated as a conditioning regimen.…”

Section: Discussionmentioning

confidence: 99%

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

Vidula¹,

Evens²,

Helenowski³

et al. 2013

MC

0

View full text Add to dashboard Cite

The optimal stem cell transplantation (SCT) conditioning therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) is not clearly defined. In a retrospective analysis, we examined 25 patients with "high risk" relapsed/refractory NHL who received busulfan, cyclophosphamide, and etoposide (Bu/Cy/VP16) conditioning with autologous or allogeneic SCT. The majority of patients had aggressive histology and 52% had primary refractory NHL. Furthermore, 48% of patients had chemotherapy-resistant disease at the time of SCT. Fifty-six percent of patients underwent allogeneic SCT, while 44% had autologous SCT. The median engraftment time for neutrophils and platelets was 13.5 and 14 days, respectively. The 100-day treatment-related mortality (TRM) was 16%, while the 2-year non-relapse mortality (NRM) rate was also 16%. At a median follow-up of 15 months, the estimated 2year disease-free survival (DFS) rate was 64% (95% confidence interval (CI): 36%-82%) and the estimated 2-year overall survival (OS) was 69% (95% CI: 40%-86%). Furthermore, the 2-year disease-specific survival (DSS) rate was 73% (95% CI: 40%-90%). Using Cox proportional hazard modeling, the International Prognostic Index at time of relapse predicted DFS and OS. Altogether, Bu/Cy/VP16 was associated with early TRM; however, late toxicities (including NRM) were uncommon resulting in relatively good survival rates in a high-risk relapsed/refractory NHL population.

show abstract

“…The pathological consultation opinions of a third class hospital in Wuhan are as follows: the left lower extremity gastrocnemius extranodal NK/T cell lymphoma (nasal type) with extensive necrosis. The tumor tissue is necrotic with only a small amount of degenerated tumor cells, whose immunohistochemistry showed: CD56, GrB, TIA-1 (+), CD3, CD30, C-myc (scattered +), Ki-67 about 95% [8]. Other CD5, CD20, CD79a, PAX-5, CD10, BCL-2, BCL-6, CyclinD1, SOX11, CD21, Mum-1, ALK-1, DES, MyoD1, Myogenin are all (-).…”

Section: Case Reportmentioning

confidence: 99%

A Case of Extranodal Nk/T Cell Lymphoma Found in Left Leg

Li

2023

RISM

0

View full text Add to dashboard Cite

show abstract

“…The pathological consultation opinions of a third class hospital in Wuhan are as follows: the left lower extremity gastrocnemius extranodal NK/T cell lymphoma (nasal type) with extensive necrosis. The tumor tissue is necrotic with only a small amount of degenerated tumor cells, whose immunohistochemistry showed: CD56, GrB, TIA-1 (+), CD3, CD30, C-myc (scattered +), Ki-67 about 95% [8]. Other CD5, CD20, CD79a, PAX-5, CD10, BCL-2, BCL-6, CyclinD1, SOX11, CD21, Mum-1, ALK-1, DES, MyoD1, Myogenin are all (-).…”

Section: Case Reportmentioning

confidence: 99%